| Similar Articles |
|---|
 |
Chemistry World
February 21, 2013
James Urquhart |
New direction for flu drugs Researchers have developed a new class of anti-flu drug that could prevent new virus strains developing resistance and help control future pandemics while more effective vaccines are prepared.   |
Chemistry World
May 14, 2008
Simon Hadlington |
Bird Flu's Drug Resistance Mapped UK scientists have shown exactly why a mutant version of the deadly bird flu virus H5N1 becomes resistant to the drug oseltamivir - marketed as Tamiflu. |
American Family Physician
December 1, 2000
Norman J. Montalto |
Updated Treatment for Influenza A and B The prevention of influenza is best accomplished with a broad-based immunization program... |
American Family Physician
July 1, 2000
Monica Preboth |
Practice Guidelines ACIP Issues Recommendations for the 2000-2001 Influenza Season |
American Family Physician
January 1, 2002
Brian J. Kingston & Charles V. Wright, Jr. |
Influenza in the Nursing Home Although influenza affects persons of all ages, the Centers for Disease Control and Prevention has identified several groups who are at increased risk for complications. One such group is residents of nursing homes or other long-term care facilities... |
American Family Physician
February 15, 2003 |
Antiviral Drugs in the Immunocompetent Host: Part II. Treatment of Influenza and Respiratory Syncytial Virus Infections |
Reactive Reports
Issue 73
David Bradley |
Fake Bird Flu Chemists have developed a rapid technique for detecting fake Tamiflu, the mainstay medication for preventing and treating bird flu. |
American Family Physician
September 1, 2006
Gregory Juckett |
Avian Influenza: Preparing for a Pandemic Preparing for a new influenza pandemic involves increasing global influenza surveillance and developing practical strategies for containing outbreaks at the source. |
The Motley Fool
October 17, 2005
Brian Gorman |
Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine. |
Managed Care
February 2005
Jack McCain |
Managed Care (and Everyone Else) Unprepared for the Next Killer Flu Could avian flu give rise to a pandemic that might rival the fearsome Spanish flu? Is the nation ready? Health plans may be called upon to administer vaccinations and identify high-risk patients, but what about he millions of Americans who lack health insurance? |
The Motley Fool
March 30, 2006
David Compton |
Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo. |
American Family Physician
January 1, 2003
Norman J. Montalto |
An Office-Based Approach to Influenza: Clinical Diagnosis and Laboratory Testing Vaccination is the primary measure for preventing morbidity and mortality from influenza. During the influenza season, family physicians must distinguish influenza from the common cold and other flu-like illnesses. |
The Motley Fool
March 16, 2006
Rich Duprey |
Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about. |
Managed Care
November 2002 |
Flu season: Most HMO formularies cover Tamiflu, Relenza As the influenza season approaches, managed care patient access to Tamiflu (oseltamivir) from Roche Laboratories and Relenza (zanamivir) from GlaxoSmithKline, the two medications indicated for influenza, looks relatively open. |
AskMen.com
Jacob Franek |
Avian Influenza 101 Here is everything you need to now about avian influenza so that you can better protect yourself. |
Chemistry World
August 1, 2013
James Urquhart |
Total synthesis outshines biotech route to anticancer drug US scientists have developed the first efficient and scalable route for the total synthesis of ingenol -- a plant-derived diterpenoid used to treat precancerous skin legions. |
Chemistry World
April 25, 2007
Richard Van Noorden |
Malaria Drug Cures Mice with Single Dose U.S. chemists have adapted a Chinese herbal medicine to create a new generation of antimalarial drugs which could solve some of the current crop's failings. |
Chemistry World
April 9, 2008
Richard Van Noorden |
The shortest recipe for Tamiflu US chemists have published the shortest synthesis to date of oseltamivir (Tamiflu), the anti-influenza drug which is also used to treat bird flu. |
Chemistry World
November 27, 2012
Andrew Turley |
Roche and the Tamiflu data The Swiss pharma company has agreed to talk to external groups about full access to data for antiviral Tamiflu (oseltamivir) tablets, according to a letter published by the British Medical Journal. |
Chemistry World
February 11, 2011
Leanne Marle |
Fighting back against antibiotic resistant bacteria Scientists in Japan have revealed how vancomycin dimers are effective against vancomycin-resistant bacteria. |
| AskMen.com |
Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
Chemistry World
April 16, 2009
Simon Hadlington |
Mass spec pinpoints flu virus types Researchers in Australia have shown that exquisitely accurate mass spectrometry can be used to distinguish between different sub-types of the influenza virus |
The Motley Fool
April 17, 2008
Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. |
American Journal of Nursing
July 2007
Victoria J. Davey |
Questions and Answers on Pandemic Influenza Striking a balance between risk and preparedness. |
Chemistry World
November 2007
Dylan Stiles |
Column: Bench Monkey Total synthesis is not immune to the vagaries of fickle fashion. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
